Toronto, ON, Canada and Hyderabad, India, October, 19, 2020 – In this free webinar, the featured speakers will discuss PROTAC technology and challenges in the field as well as opportunities and strategies for developing PROTACs in cancer and inflammation. Attendees will learn about the available tools and assays for mechanistic profiling and DMPK optimization for oral bioavailability.
About the webinar
Proteolysis targeting chimera or PROTAC is a novel drug discovery strategy that has brought a paradigm shift and significant opportunity to transform the way medicinal chemistry and drug discovery programs are currently planned and executed. With sub-stoichiometric catalytic mode of action, PROTACs reduce the need for target occupancy as necessitated with traditional small molecule inhibitors. PROTACs hold great promise to target highly mutable kinases and signaling proteins, which promote cancer and drug resistance (e.g., KRAS, BRAF and EGFR).
This webinar will focus on our efforts with PROTACs in the areas of inflammation and cancer. Specifically, we will discuss challenges and opportunities for developing PROTACs in the areas of autoimmune and inflammatory diseases driven by IL-1R/TLR1 signaling and inflammasome activation and in potentially undruggable epigenetic pathways that involve bromodomain proteins, histone acetyltransferases and deacetylases.
The webinar will also address some of the DMPK challenges in developing PROTACs and strategies and optimizations that might aid the development of orally bioavailable PROTAC candidates.
Join Amar Thyagarajan, Ph.D., Global Strategy Head and Head of North America BD (Biology Solutions), GVK Biosciences and Aragen Biosciences and Venkatesh Babu Jayaraman, Principal Scientific Manager, GVK Biosciences in a live webinar on Friday, October 30, 2020 at 11am EDT (3pm GMT/UK).
For more information or to register for this event, visit Targeted Protein Degradation in Inflammation and Cancer Therapy.
About GVK BIO
GVK BIO, a leading Contract Research & Development Organization servicing the global Life-sciences industry, is headquartered in Hyderabad, India with operations in five sites including Aragen Bioscience, Inc. in California, USA. Established in 2001, GVK BIO has over 19 years of experience across the Research and Development value chain with a focus on speed and quality while ensuring safety and compliance. GVK BIO’s team of over 2500 highly qualified scientists, backed by a no-conflict business model, well-defined and scalable processes, modern facilities, and a strong customer-centric partnering approach, focus on bringing its customers’ products to market. For more information, visit www.gvkbio.com
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private and academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
For further information, please contact:
Sarat Patanaik, GVK BIO,